C1; C4; COPD; ECM; basement membrane; cell turnover; collagen; lamina reticularis; type I collagen; type IV collagen
Abstract :
[en] BACKGROUND: The role of the extracellular matrix (ECM) structure and remodeling thereof in lung diseases is gaining importance. Pathology-related changes in ECM turnover may result in deleterious changes in lung architecture, leading to disease in the small airways. Here, degradation fragments of type I (C1M), type IV (alpha1 chain, C4M2), and type IV (alpha3 chain, C4Ma3) collagen, all degraded by metalloproteinases and the pro-form of collagen type V (PRO-C5) were investigated and associated with COPD severity and outcome. METHODS: In a prospective, observational, multicenter study including 498 patients with COPD Gold Initiative for Chronic Obstructive Lung Disease stage 2 to 4, ECM markers were assessed in serum at stable state, exacerbation, and at follow-up 4 weeks after exacerbation. RESULTS: At stable state, there was a significant inverse association between FEV1 % predicted and C1M, C4Ma3, and Pro-C5. C1M, C4M2, C4Ma3, and Pro-C5 were associated with BMI, airflow obstruction, dyspnea, and exercise capacity (BODE) index and the modified Medical Research Council (MMRC) score. C1M, C4M2, C4Ma3, and Pro-C5 were significantly increased from stable state to exacerbation and decreased at follow-up. Furthermore, the biomarkers were significantly higher during severe exacerbation compared with moderate exacerbation. Multivariate analysis adjusted for BMI, MMRC score, unadjusted Charlson score, and FEV1 %predicted showed a significant influence of C1M, C4Ma3, and C4M2 on time to exacerbation. None of the biomarkers were predictors for mortality. CONCLUSIONS: Serologically assessed collagen remodeling appears to play a significant role in COPD severity (airflow limitation, dyspnea) and disease outcome (time to exacerbation and prognosis as assessed by the BODE index).
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Schumann, Desiree M.
Leeming, Diana
Papakonstantinou, Eleni
Blasi, Francesco
Kostikas, Konstantinos
Boersma, Wim
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Turato, G., Zuin, R., Saetta, M., Pathogenesis and pathology of COPD. Respiration 68:2 (2001), 117–128.
Saetta, M., Turato, G., Maestrelli, P., Mapp, C.E., Fabbri, L.M., Cellular and structural bases of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163:6 (2001), 1304–1309.
Dunsmore, S.E., Treatment of COPD: a matrix perspective. Int J Chron Obstruct Pulmon Dis 3:1 (2008), 113–122.
Liesker, J.J.W., Hacken, N.H.T., Zeinstra-Smith, M., Rutgers, S.R., Postma, D.S., Timens, W., Reticular basement membrane in asthma and COPD: similar thickness, yet different composition. Int J Chron Obstruct Pulmon Dis 4 (2009), 127–135.
Menter, D.G., DuBois, R.N., Prostaglandins in cancer cell adhesion, migration and invasion. Int J Cell Biol, 2012, 2012 723419.
Postma, D.S., Timens, W., Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 3:5 (2006), 434–439.
Wilkes, D.S., Chew, T., Flaherty, K.R., et al. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J 45:5 (2015), 1393–1402.
Braun, R.K., Martin, A., Shah, S., et al. Inhibition of bleomycin-induced pulmonary fibrosis through pre-treatment with collagen type V. J Heart Lung Transplant 29:8 (2010), 873–880.
Leeming, D.J., Sand, J.M., Nielsen, M.J., et al. Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomarker Insights 7 (2012), 119–126.
Stolz, D., Leeming, D.J., Kristensen, J.H.E., et al. Systemic biomarkers of collagen and elastin turnover are associated with clinically relevant outcomes in COPD. Chest 151:1 (2017), 47–59.
Sand, J.M.B., Leeming, D.J., Byrjalsen, I., et al. High levels of biomarkers of collagen remodeling are associated with increased mortality in COPD - results from the ECLIPSE study. Resp Res, 17(125), 2016.
Sand, J.M.B., Knox, A.J., Lange, P., et al. Accelerated extracellular matrix turnover during exacerbations of COPD. Resp Res, 16(69), 2015.
Bihlet, A.R., Karsdal, M.A., Sand, J.M.B., et al. Biomarkers of extracellular matrix turnover are associated with emphysema and eosinophilic-bronchitis in COPD. Resp Res, 18(22), 2017.
Jenkins, R.G., Simpson, J.K., Saini, G., et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 3:6 (2015), 462–472.
Leeming, D.J., Nielsen, M.J., Dai, Y., et al. Enzyme-linked immunosorbent serum assay specific for the 7S domain of Collagen Type IV (P4NP 7S): a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res 42:5 (2012), 482–493.
Karsdal, M.A., Nielsen, M.J., Sand, J.M., et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 11:2 (2013), 70–92.
Karsdal, M.A., Krarup, H., Sand, J.M., et al. Review article: the efficacy of biomarkers in chronic fibroproliferative disease - early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 40:3 (2014), 233–249.
Salazar, L.M., Herrera, A.M., Fibrotic response of tissue remodeling in COPD. Lung 189:2 (2011), 101–109.
Kranenburg, A.R., Willems-Widyastuti, A., Mooi, W.J., et al. Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Clin Pathol 126:5 (2006), 725–735.
Crosby, L.M., Waters, C.M., Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol 298:6 (2010), L715–L731.
Churg, A., Zhou, S., Wright, J.L., Series ‘matrix metalloproteinases in lung health and disease’. Matrix metalloproteinases in COPD. Eur Respir J 39:1 (2012), 197–209.
Cane, J.L., Mallia-Millanes, B., Forrester, D.L., Knox, A.J., Bolton, C.E., Johnson, S.R., Matrix metalloproteinases -8 and -9 in the airways, blood and urine during exacerbations of COPD. COPD 13:1 (2016), 26–34.
Grolimund, E., Kutz, A., Marlowe, R.J., et al. Long-term prognosis in COPD exacerbation: role of biomarkers, clinical variables and exacerbation type. COPD 12:3 (2015), 300–310.
Guo, L., Li, D., Dong, S., Wan, D., Yang, B., Huang, Y., Mutation analysis of COLD4A3 and COLD4A4 genes in a Chinese autosomal-dominant Alport Syndrome family. J Genet 96:2 (2017), 389–392.
Dragsbaek, K., Neergaard, J.S., Hansen, H.B., et al. Matrix metalloproteinase mediated type 1 collagen degradation - an independent risk factor for mortality in women. EBioMedicine 2:7 (2015), 723–729.
Priftis, K.N., Loukopoulou, S., Magkou, C., Sitaras, N.M., Increased glycosaminoglycans in the urine of asthmatic children on inhaled corticosteroids. Pediatr Allergy Immunol 17:3 (2006), 194–198.
Jeffery, P.K., Godfrey, R.W., Aedelroth, E., Nelson, F., Rogers, A., Johansson, S.-A., Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am Rev Respir Dis 145:4 pt 1 (1992), 890–899.
Soltani, A., Walters, E.H., Reid, D.W., et al. Inhaled corticosteroid normalizes some but not all airway vascular remodeling in COPD. Int J COPD 11 (2016), 2359–2367.
Goulet, S., Bihl, M.P., Gambazzi, F., Tamm, M., Roth, M., Opposite effect of corticosteroids and long-acting beta2-agonists on serum- and TGF-beta-induced extracellular matrix deposition by primary human lung fibroblasts. J Cell Physiol 210:1 (2007), 167–176.
Leeming, D.J., Byrjalsen, I., Sand, J.M., et al. Biomarkers of collagen turnover are related to annual change in FEV1 in patients with chronic obstructive pulmonary disease within the ECLIPSE study. BMC Pulmon Med, 17(164), 2017.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
